Statement: Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort 1 of the secondary trial. milliliter per microgram per meter squared per day is a unit of concentration equal to milliliter divided by microgram per meter squared per day.
Primary_evidence: Adverse Events 1:   Total: 0/34 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 6/62 (9.68%)   Musculoskeletal * 1/62 (1.61%)   Mood Alteration: Depression * 1/62 (1.61%)   renal - Other * 1/62 (1.61%)   Obstruction, GU: Uterus * 1/62 (1.61%)   Sexual * 0/62 (0.00%)   Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%)   Ulceration * 1/62 (1.61%) Adverse Events 2:   Total: 1/64 (1.56%)   Musculoskeletal * 0/64 (0.00%)   Mood Alteration: Depression * 0/64 (0.00%)   renal - Other * 0/64 (0.00%)   Obstruction, GU: Uterus * 0/64 (0.00%)   Sexual * 1/64 (1.56%)   Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%)   Ulceration * 0/64 (0.00%)